A prospective observational cohort study on patients with PSA levels ranging from 4 to 10 ng/ml at opportunistic screening: management and responses to ciprofloxacin 1000 mg.
OBJECTIVE
To analyze in the real life clinical setting the effect offluorchinolones treatment in the management of elevated (4-10 ng/ml) prostate-specific antigen level we conducted an observational prospective cohort study.


METHODS
Eligible for the study were subjects aged 45-75 years with a PSA level 4-10 ng/ml, consecutively observed during their routine practice by first level outpatients urologic centres.


RESULTS
A total of 740 patients, mean value of total PSA at study entry: 5.8 (SD = 1.6) entered the study. A total of 616 subjects were treated with ciprofloxacin. The mean serum t-PSA value decreased between study entry and final visit of 1.31 ng/ml (SD 4.19) (p < 0.05). At follow up visit the 49.4% (95% CI 44.1-55.5) of patients had PSA level < 4 ng/ml. In comparison with patients with t-PSA < = 5.0 ng/ml, the OR of having normal t-PSA value at follow up were respectively 0.61 (95% CI 0.4-0.9) and 0.23 (0.1-0.3) for patients with t-PSA 5.1-6.2 and 2 6.3.


CONCLUSIONS
The results of this large observational prospective study showed that a 2-3 week course of treatment with ciprofloxacin 1000 mg is able to significantly reduce the PSA level in about 50% of men aged 45-75 years with t-PSA levels of 4-10 ng/ml.
Department of Urology, University of Naples Federico II, Napoli, Italy. verzep@hotmail.it
Paolo
P
Verze
Fabio
F
Parazzini
Davide
D
Arcaniolo
Sonia
S
Cipriani
Vincenzo
V
Mirone
D000368:Aged; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000494:pharmacology; D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects*
D002939:Ciprofloxacin; D017430:Prostate-Specific Antigen